SG156689A1 - Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate - Google Patents
Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediateInfo
- Publication number
- SG156689A1 SG156689A1 SG200907192-9A SG2009071929A SG156689A1 SG 156689 A1 SG156689 A1 SG 156689A1 SG 2009071929 A SG2009071929 A SG 2009071929A SG 156689 A1 SG156689 A1 SG 156689A1
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- novel process
- isoxazoline derivative
- intermediate used
- isoxazoline
- Prior art date
Links
- 150000002547 isoxazolines Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050016203 | 2005-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG156689A1 true SG156689A1 (en) | 2009-11-26 |
Family
ID=36927605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200907192-9A SG156689A1 (en) | 2005-02-26 | 2006-02-21 | Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8044080B2 (es) |
| EP (1) | EP1851214B1 (es) |
| JP (1) | JP4961357B2 (es) |
| KR (1) | KR100774999B1 (es) |
| CN (1) | CN101128459B (es) |
| AP (1) | AP2374A (es) |
| AR (1) | AR055314A1 (es) |
| AU (1) | AU2006217293B2 (es) |
| BR (1) | BRPI0607330B1 (es) |
| CA (1) | CA2598347C (es) |
| DK (1) | DK1851214T3 (es) |
| EA (1) | EA013005B1 (es) |
| ES (1) | ES2394480T3 (es) |
| IL (1) | IL185226A0 (es) |
| MA (1) | MA29311B1 (es) |
| MX (1) | MX2007010338A (es) |
| MY (1) | MY149181A (es) |
| NO (1) | NO341347B1 (es) |
| NZ (1) | NZ560805A (es) |
| PE (1) | PE20061076A1 (es) |
| PL (1) | PL1851214T3 (es) |
| PT (1) | PT1851214E (es) |
| SG (1) | SG156689A1 (es) |
| SI (1) | SI1851214T1 (es) |
| TW (1) | TWI377205B (es) |
| UA (1) | UA94395C2 (es) |
| WO (1) | WO2006090997A1 (es) |
| ZA (1) | ZA200707202B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101299720B1 (ko) * | 2006-08-16 | 2013-08-28 | 주식회사 엘지생명과학 | 3-아미노-5-플루오로-4-디알콕시펜탄산 에스테르의 새로운제조방법 |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| AR072181A1 (es) * | 2008-07-11 | 2010-08-11 | Gilead Sciences Inc | Metodo de tratamiento y composiciones farmaceuticas que comprenden (r)-n-((2s,3s)-2-(fluorometil)-2-hidroxi-5-oxo-tetrahidrofuran-3-il)-5-isopropil-3-(isoquinolin-1-il)-4,5-dihidroisoxazol-5-carboxamida y uso |
| TW201012816A (en) * | 2008-07-11 | 2010-04-01 | Gilead Sciences Inc | Method of treatment and pharmaceutical compositions |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| EP2900661B1 (en) * | 2012-09-28 | 2016-10-26 | Bayer CropScience AG | Quinoline isoxazolin derivatives for plant disease control |
| JP2017095353A (ja) * | 2014-03-27 | 2017-06-01 | 日本曹達株式会社 | イソオキサゾリン−5−カルボキサミド化合物および有害生物防除剤 |
| US11434212B2 (en) * | 2017-01-23 | 2022-09-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bicyclic compound as a caspase inhibitor |
| EP3939976B1 (en) * | 2019-04-19 | 2024-05-01 | Lg Chem, Ltd. | Prodrug of caspase inhibitor |
| KR102442103B1 (ko) * | 2019-04-30 | 2022-09-08 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
| US20220226306A1 (en) * | 2019-05-31 | 2022-07-21 | Lg Chem, Ltd. | Composition for caspase inhibitor prodrug injection |
| WO2020242234A1 (ko) * | 2019-05-31 | 2020-12-03 | 주식회사 엘지화학 | 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법 |
| CA3185212A1 (en) * | 2020-08-05 | 2022-02-10 | Lg Chem, Ltd. | Use of caspase inhibitor for alleviating or treating osteoarthritis |
| WO2022114876A1 (ko) | 2020-11-30 | 2022-06-02 | 주식회사 엘지화학 | 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법 |
| KR102670554B1 (ko) * | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
| EP4458347A4 (en) | 2022-01-24 | 2025-04-30 | LG Chem, Ltd. | ISOXAZOLINE DERIVATIVE-CONTAINING INJECTABLE FORMULATION |
| EP4467126A4 (en) * | 2022-02-23 | 2025-04-30 | LG Chem, Ltd. | Injectable formulation containing isoxazoline derivative and method for producing the same |
| KR20230141971A (ko) | 2022-03-24 | 2023-10-10 | 주식회사 엘지화학 | 이소옥사졸린 유도체를 포함하는 주사용 제제 및 이의 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100373375B1 (ko) * | 1998-04-03 | 2003-06-12 | 주식회사 엘지생명과학 | 인터루킨-1b-컨버팅효소및아포파인/cpp-32에대한저해제 |
| KR19990079267A (ko) * | 1998-04-03 | 1999-11-05 | 성재갑 | 이소옥사졸(또는 이소옥사졸린) 구조를 갖는 파네실 전이효소억제제 |
| AU7322300A (en) | 1999-09-17 | 2001-04-24 | Lg Chem Investment Ltd. | Caspase inhibitor |
| WO2001021599A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chemical Ltd. | Caspase inhibitor |
| KR100594544B1 (ko) * | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | 이소옥사졸린 구조를 갖는 캐스파제 저해제 |
| US7446127B2 (en) * | 2003-08-27 | 2008-11-04 | Sk Holdings Co, Ltd. | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders |
-
2006
- 2006-02-10 KR KR1020060013107A patent/KR100774999B1/ko active Active
- 2006-02-15 TW TW095105039A patent/TWI377205B/zh active
- 2006-02-21 SI SI200631425T patent/SI1851214T1/sl unknown
- 2006-02-21 AU AU2006217293A patent/AU2006217293B2/en active Active
- 2006-02-21 NZ NZ560805A patent/NZ560805A/en unknown
- 2006-02-21 SG SG200907192-9A patent/SG156689A1/en unknown
- 2006-02-21 CA CA2598347A patent/CA2598347C/en active Active
- 2006-02-21 JP JP2007556969A patent/JP4961357B2/ja active Active
- 2006-02-21 CN CN2006800059846A patent/CN101128459B/zh active Active
- 2006-02-21 MX MX2007010338A patent/MX2007010338A/es active IP Right Grant
- 2006-02-21 EA EA200701810A patent/EA013005B1/ru unknown
- 2006-02-21 BR BRPI0607330-1A patent/BRPI0607330B1/pt active IP Right Grant
- 2006-02-21 PL PL06716026T patent/PL1851214T3/pl unknown
- 2006-02-21 US US11/816,801 patent/US8044080B2/en active Active
- 2006-02-21 ES ES06716026T patent/ES2394480T3/es active Active
- 2006-02-21 EP EP06716026A patent/EP1851214B1/en active Active
- 2006-02-21 AP AP2007004103A patent/AP2374A/xx active
- 2006-02-21 UA UAA200709610A patent/UA94395C2/ru unknown
- 2006-02-21 PT PT06716026T patent/PT1851214E/pt unknown
- 2006-02-21 DK DK06716026.7T patent/DK1851214T3/da active
- 2006-02-21 WO PCT/KR2006/000576 patent/WO2006090997A1/en not_active Ceased
- 2006-02-22 MY MYPI20060748A patent/MY149181A/en unknown
- 2006-02-24 PE PE2006000221A patent/PE20061076A1/es active IP Right Grant
- 2006-02-24 AR ARP060100679A patent/AR055314A1/es active IP Right Grant
-
2007
- 2007-08-13 IL IL185226A patent/IL185226A0/en active IP Right Grant
- 2007-08-17 MA MA30152A patent/MA29311B1/fr unknown
- 2007-08-24 ZA ZA200707202A patent/ZA200707202B/xx unknown
- 2007-09-26 NO NO20074895A patent/NO341347B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG156689A1 (en) | Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate | |
| MY147732A (en) | Process for the preparation of 2-substituted-5- (1-alkylthio) alkylpyridines | |
| MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
| WO2005108358A3 (en) | Pyrrolidine derivatives useful as bace inhibitors | |
| IL188919A (en) | Process for the preparation of mandipropamide and its derivatives as well as its intermediates | |
| TW200624426A (en) | BACE inhibitors | |
| SG152274A1 (en) | Dalbavancin compositions for treatment of bacterial infections | |
| TW200716525A (en) | Process for preparation of sulfamide derivatives | |
| TW200730518A (en) | Crystalline forms of docetaxel and processes for their preparation | |
| TW200613308A (en) | Cyclobutanetetracarboxylate compound and preparation method thereof | |
| IL200000A (en) | Process for Preparing 5- (1- Alkylthio) Alkylpyridines are Stored in Position 2 and Its Compounds | |
| NO20070550L (no) | Fremgangsmate for fremstilling av pyrrolotriazinforbindelser | |
| NO20073276L (no) | Metode for fremstilling av aminoetoksybenzylalkoholer | |
| WO2007075870A3 (en) | Processes for taxane derivatives and intermediates useful therein | |
| IL189286A0 (en) | Novel cysteine protease inhibitors and their therapeutic applications | |
| SG153856A1 (en) | Chemical process | |
| NO20091140L (no) | Fremgangsmate for fremstilling av polyester nanokompositter | |
| TW200510323A (en) | Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives | |
| SG148168A1 (en) | Genetically modified microorganism and process for production of macrolide compound using the microorganism | |
| SG142306A1 (en) | Methods for neuroprotection | |
| WO2007063556A3 (en) | An improved and industrial process for the preparation of alfuzosin hydrochloride and its novel polymorphs | |
| SG158857A1 (en) | Preparation of ketone amides | |
| SG144920A1 (en) | Method and intermediates for the preparation of derivatives of n-(1- benzhydrylazetidin-3-yl)-n-phenylmethylsulphonamide | |
| TW200800972A (en) | Process for the preparation of dioxane derivatives | |
| TW200732342A (en) | Process for the preparation of purified crystalline CCI-779 |